Drug Safety

, Volume 32, Issue 12, pp 1123–1134 | Cite as

Benefit-Risk Assessment of Leflunomide

An Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing
  • Nicola Alcorn
  • Sarah Saunders
  • Rajan Madhok
Review Article


Evidence is accumulating for the early sustained usage of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis. Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998. Postmarketing surveillance, case reports and observational studies have highlighted less common or unexpected adverse events. Therefore, it is appropriate that we review the benefit-risk profile of leflunomide after 10 years of widespread usage. A wide-based search of relevant literature was performed to formulate this assessment.

The improvements in rheumatoid arthritis shown by double-blind, randomized controlled trials (RCTs) of leflunomide have now been shown to be maintained beyond 4 years in open-label extension studies. Leflunomide is comparable to methotrexate, but better than sulfasalazine at 24 months in only one study. However, tolerance in clinical practice research shows higher than expected withdrawal rates due to both toxicity and lack of efficacy when compared with methotrexate and placebo.

Adverse events reported include gastrointestinal upset, hypertension, headache, hepatotoxicity and hair loss, as well as predisposition to infection and peripheral neuropathy. The incidence of gastrointestinal adverse effects for leflunomide is similar to sulfasalazine but higher than those seen with methotrexate. Serious drug-induced hepatotoxicity leading to hospitalization is rare (0.02%), but isolated fatalities from liver failure have been documented. It is considered likely, but not yet proven, that there may be an increased incidence of weight loss and interstitial lung disease with leflunomide.

Leflunomide in combination with methotrexate or sulfasalazine is an effective regimen in RCTs utilizing placebo controls, but more research is needed to confirm its effectiveness in combination with other DMARDs, particularly biologicals.

The active metabolite of leflunomide is teratogenic in animal studies and is also found in breast milk. Therefore, contraception is advised in both males and females of child-bearing potential. There are genetic, pharmacokinetic and biochemical reasons to explain variation in both patient response and adverse event profile. Hence, blood and blood pressure monitoring are recommended and therapeutic drug monitoring should be considered in clinical nonresponders.

Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate. However, adverse effects necessitate frequent monitoring. It should be used with caution in those of child-bearing potential and with pre-existing lung and liver disease.


Rheumatoid Arthritis Infliximab Interstitial Lung Disease Rheumatol Sulfasalazine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38(11): 1595–603PubMedCrossRefGoogle Scholar
  2. 2.
    Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159(21): 2542–50Google Scholar
  3. 3.
    Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multi-centre trial. European Leflunomide Study Group. Lancet 1999; 353(9149): 259–66Google Scholar
  4. 4.
    HMR’s Arava launched in US. Scrip 1998; 2387: 19Google Scholar
  5. 5.
    HMR’s Arava launched in EU. Scrip 1999; 2471: 22Google Scholar
  6. 6.
    Ruckermann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998; 273(21): 21682–91CrossRefGoogle Scholar
  7. 7.
    Cherwinski HM, Cohn RG, Cheung P, et al. The immuno-suppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275: 1043–9PubMedGoogle Scholar
  8. 8.
    Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58(6): 1137–64PubMedCrossRefGoogle Scholar
  9. 9.
    Xu X, Blinder L, Shen J, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and auto immune disease in MRL/MpJ-Ipr/Ipr mice. J Immunol 1997; 159: 167–74PubMedGoogle Scholar
  10. 10.
    Kraan MC, Reece RJ, Barg BE, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomised, double-blind, parallel-design clinical trial in thirty-nine patients at two centres. Arthritis Rheum 2000; 43(8): 1820–30PubMedCrossRefGoogle Scholar
  11. 11.
    Litinsrky I, Paran D, Levartovsky D, et al. The effect of leflunomide on clinical parameters and serum levels of IL6, IL10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine 2006; 33(2): 106–10CrossRefGoogle Scholar
  12. 12.
    Cao WW, Kao PN, Aoki Y, et al. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine TGF-B1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996; 28: 3079–80PubMedGoogle Scholar
  13. 13.
    Kraan MC, De Koster BM, Elferink JG, et al. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: finding in prospective randomised double blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43(7): 1488–95PubMedCrossRefGoogle Scholar
  14. 14.
    Siesmasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 27(61): 635–42CrossRefGoogle Scholar
  15. 15.
    Siesmasko KF, Chong AS, Jack HM, et al. Inhibition of JAK-3 and Stat 6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IG1 production. J Immunol 1998; 160(15): 1581–8Google Scholar
  16. 16.
    Weithmann KU, Jescke S, Schlotte V. Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation. Agent Actions 1994; 41: 164–70CrossRefGoogle Scholar
  17. 17.
    Hoechst Marion Rousel. Arava (leflunomide) prescribing information. Kansas City (MO): Hoechst Marion Roussel Inc., 1998 SepGoogle Scholar
  18. 18.
    Hoechst Marion Rousel. Arava: pharmacokinetics. Kansas City (MO): Hoechst Marion Roussel Inc., 1998. (Data on file)Google Scholar
  19. 19.
    Hoechst Marion Rousel. Arava: washout with cholestyramine and activated charcoal. Kansas City (MO): Hoechst Marion Roussel Inc., 1998. (Data on file)Google Scholar
  20. 20.
    Siva C, Eisen SA, Shepherd R, et al. Leflunomide use during the first 33 months after Food and Drug Administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum 2003; 42(6): 745–51CrossRefGoogle Scholar
  21. 21.
    Chan V, Charles BG, Tett SE. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Pharm 2005; 60(3): 257–64CrossRefGoogle Scholar
  22. 22.
    Jaimes-Hernandez J, Robles-San Rroman M, Suarez-Otero R, et al. Rheumatoid arthritis treatment weekly leflunomide: an open-label study. J Rheumatol 2004; 31(2): 235–7PubMedGoogle Scholar
  23. 23.
    Poor G, for the Leflunomide Multinational Study Group and Strand V. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomised trial. Rheumatol 2004; 43: 744–9CrossRefGoogle Scholar
  24. 24.
    Jakez-Ocampo J, Richaud-Patin Y, Simon JA, et al. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine 2002; 69(3): 307–11PubMedCrossRefGoogle Scholar
  25. 25.
    Weber W, Harnisch L. Use of a population pharmacokintic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 1997; 40(9): S153Google Scholar
  26. 26.
    van Roon EN, Jansen TLTA, van der Laar MAFJ, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 569–74PubMedCrossRefGoogle Scholar
  27. 27.
    Kis E, Nagy T, Jani M, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis 2009; 68(7): 1201–7PubMedCrossRefGoogle Scholar
  28. 28.
    Hoechst Marion Rousell. Arava: drug interactions. Kansas City (MO): Hoechst Marion Roussel Inc., 1998. (Data on file)Google Scholar
  29. 29.
    Lim V, Pande I. Leflunomide can potentiate the anticoagulant effects of warfarin [letter]. BMJ 2002; 325: 1333PubMedCrossRefGoogle Scholar
  30. 30.
    Wolfe F. The effect of smoking on clinical/laboratory and radiographic status in rheumatoid arthritis. J Rheumatol 2000; 27(3): 630–7PubMedGoogle Scholar
  31. 31.
    Saag KG, Cerhan JR, Kolluri S, et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56(8): 463–9PubMedCrossRefGoogle Scholar
  32. 32.
    Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001 Sep; 44(9): 1984–92CrossRefGoogle Scholar
  33. 33.
    Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulphasalazine. Ann Rheum Dis 2001 Oct; 60(10): 913–23PubMedCrossRefGoogle Scholar
  34. 34.
    Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun; 39(6): 655–65CrossRefGoogle Scholar
  35. 35.
    Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol 2003 Jun; 30(6): 1182–90PubMedGoogle Scholar
  36. 36.
    Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(6): 1530–42PubMedCrossRefGoogle Scholar
  37. 37.
    Pincus T, Summey JA, Soraci Jr SA, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983; 26: 1346–53PubMedCrossRefGoogle Scholar
  38. 38.
    Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8-item HAQ (DHAQ), and a rescored 20-item HAQ (HAQ20): analyses in 2491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001; 28(5): 982–9PubMedGoogle Scholar
  39. 39.
    van der Heijde D. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl. 2: 74–8PubMedGoogle Scholar
  40. 40.
    Sharp JT, Lidsky MD, Collins LC, et al. Methods of scoring the progression of radiographic changes in rheumatoid arthritis, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706–20PubMedCrossRefGoogle Scholar
  41. 41.
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977; 18: 481–91Google Scholar
  42. 42.
    Kalden JR, Schattenkirchner M, Sorensen H, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow up study. Arthritis Rheum 2003 Jun; 48(6): 1513–20PubMedCrossRefGoogle Scholar
  43. 43.
    van der Heijde D, Kalden J, Scott D, et al. Long term evaluation of radiographic progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis 2004 Jun; 63(6): 737–9PubMedCrossRefGoogle Scholar
  44. 44.
    van Roon EN, Jansen TL, Mourad L, et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharm 2004; 57(6): 790–7CrossRefGoogle Scholar
  45. 45.
    Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvements in clinical trials. Ann Rheum Dis 2006; 65: 227–33PubMedCrossRefGoogle Scholar
  46. 46.
    Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; (1): CD002047Google Scholar
  47. 47.
    McEntegart A. Leflunomide. In: Capell H, Madhok R, McInnes IB, editors. Practical prescribing guidelines in rheumatoid arthritis. Martin Dunitz, 2003: 101–12Google Scholar
  48. 48.
    Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease modifying medications for rheumatoid arthritis. Ann Int Med 2008; 148(2): 124–34PubMedGoogle Scholar
  49. 49.
    The European Agency for the Evaluation of Medicinal Products. EMEA public statement on leflunomide (ARAVA): severe and serious hepatic reactions, 12 March 2001 [online]. Available from URL: [Accessed 2009 Sep 22]
  50. 50.
    Van Roon EN, Jansen TL, Houtman NM, et al. Leflunomide for the treatment of rheumatoid arthrtis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004; 27(5): 345–52PubMedCrossRefGoogle Scholar
  51. 51.
    Charlatan F. Arthritis drug should be removed from market, says consumer group [letter]. BMJ 2002; 324: 869CrossRefGoogle Scholar
  52. 52.
    Food and Drug Administration, Arthritis Advisory Committee. Briefing information: Arava™ (leflunomide), March 5, 2003 [online]. Available from URL: [Accessed 2009 Jul 30]
  53. 53.
    Suissa S, Ernst P, Hudson M, et al. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004; 117(2): 87–92PubMedCrossRefGoogle Scholar
  54. 54.
    Sevilla-Mantila C, Ortega L, Agundez JA, et al. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004; 36(1): 82–4CrossRefGoogle Scholar
  55. 55.
    Tan SC, New LS, Chan EC. Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine. Toxicol Lett 2008; 180(3): 174–81PubMedCrossRefGoogle Scholar
  56. 56.
    Tanaka N, Sakahashi H, Sato E, et al. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 2003; 9(2): 115–8PubMedCrossRefGoogle Scholar
  57. 57.
    Jenks KA, Stamp LK, O’Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol 2007; 34(11): 2201–3PubMedGoogle Scholar
  58. 58.
    Ezanuer RJ, Khan KJ. Pneumocystitis carnii pneumonia associated with leflunomide therapy for rheumatoid arthritis. J Clin Rheum 2002; 8(1): 64–6Google Scholar
  59. 59.
    Richards BL, Spies J, McGill N, et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J 2007; 37(2): 101–7PubMedCrossRefGoogle Scholar
  60. 60.
    Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004; 43(12): 1201–4PubMedCrossRefGoogle Scholar
  61. 61.
    Takeishi M, Akiyama Y, Akiba H, et al. Leflunomide-induced acute interstitial pneumonia. J Rheumatol 2005; 32: 1160–3PubMedGoogle Scholar
  62. 62.
    McCurry J. Japan deaths spark concern over arthritis drug [letter]. Lancet 2004; 363(9407): 461PubMedCrossRefGoogle Scholar
  63. 63.
    Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54(5): 1435–9PubMedCrossRefGoogle Scholar
  64. 64.
    Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007; 56(6): 2094–6PubMedCrossRefGoogle Scholar
  65. 65.
    Kanbe K, Inoue K, Chiba J, et al. The side-effects and efficacy of leflunomide in Japanese patients with rheumatoid arthritis. APLAR J Rheumatol 2005; 8(2): 114–8CrossRefGoogle Scholar
  66. 66.
    Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators’ Group. J Rheumatol Suppl 1998; 53: 27–32PubMedGoogle Scholar
  67. 67.
    Coblyn JS, Shadick N, Helfgott S. Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis Rheum 2001; 44(5): 1048–51PubMedCrossRefGoogle Scholar
  68. 68.
    van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl 2004; 71: 21–4PubMedGoogle Scholar
  69. 69.
    Dale J, Alcorn N, Capell H, et al. Combination therapy for rheumatoid arthritis: methotrexate and sulphaslazine together or with other DMARDs. Nat Clin Pract Rheumatol 2007; 3(80): 450–8PubMedCrossRefGoogle Scholar
  70. 70.
    Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42(7): 1322–8PubMedCrossRefGoogle Scholar
  71. 71.
    Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137(9): 726–33PubMedGoogle Scholar
  72. 72.
    Kremer J, Genovese M, Cannon GW, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004; 31(8): 1521–31PubMedGoogle Scholar
  73. 73.
    Cohen S, Schiff M, Weaver A, et al. Leflunomide (LEF) as an initial therapy with methotrexate (MTX) added for rheumatoid arthritis patients with active disease [abstract]. Arthritis Rheum 2002; 46 Suppl.: S352Google Scholar
  74. 74.
    Dougados M, Emery P, Lemmel EM, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003; 30(12): 2572–9PubMedGoogle Scholar
  75. 75.
    Hansen KE, Cush J, Singhal A, et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 2004; 51(2): 228–32PubMedCrossRefGoogle Scholar
  76. 76.
    Patel S, Bergen W, Kraemer A, et al. Efficacy and safety of Remicade (infliximab) plus Arava (leflunomide) in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001; 44 Suppl.: S84Google Scholar
  77. 77.
    Perdriger A, Combe B, Kuntz JL, et al. A French multi-centre retrospective study on the efficacy and safety of leflunomide in association with DMARDs other than methotrexate [abstract]. Ann Rheum Dis 2004; 50 Suppl.: 488Google Scholar
  78. 78.
    Godinho F, Godfrin B, El Mahou S, et al. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22(3): 328–30PubMedGoogle Scholar
  79. 79.
    Ortiz Garcia AM, Gonzalez-Alvaro I, Rosello Pardo R, et al. Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis [letter]. Clin Exp Rheumatol 2004; 22(6): 790PubMedGoogle Scholar
  80. 80.
    Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) 2002; 41(6): 631–7CrossRefGoogle Scholar
  81. 81.
    Struppler CI, Theis W, Schattenkirchner M, et al. Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis (RA) [abstract]. Ann Rheum Dis 2002; 61: S388Google Scholar
  82. 82.
    Bingham SJ, Buch MH, Kerr MA, et al. Induction of anti-nuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 2004; 50(12): 4072–3PubMedCrossRefGoogle Scholar
  83. 83.
    Flendrie M, Creemers MC, Welsing PM, et al. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford) 2005; 44(4): 472–8CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Nicola Alcorn
    • 1
  • Sarah Saunders
    • 1
  • Rajan Madhok
  1. 1.The Centre for Rheumatic DiseasesGlasgow Royal InfirmaryGlasgowUK

Personalised recommendations